Capital Analysts LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Analysts LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53K	Buy	119 +3	+3%	+$1.4K	﹤0.01%	928
2025 Q4	$52K	Hold	116	–	–	﹤0.01%	907
2025 Q3	$45K	Buy	116 +29	+33%	+$12.1K	﹤0.01%	908
2025 Q2	$39K	Hold	87	–	–	﹤0.01%	874
2025 Q1	$42K	Buy	87 +10	+13%	+$4.66K	﹤0.01%	830
2024 Q4	$31K	Sell	77 -3	-4%	-$1.39K	﹤0.01%	847
2024 Q3	$37K	Hold	80	–	–	﹤0.01%	786
2024 Q2	$37K	Buy	80 +3	+4%	+$1.3K	﹤0.01%	767
2024 Q1	$32K	Hold	77	–	–	﹤0.01%	751
2023 Q4	$31K	Hold	77	–	–	﹤0.01%	748
2023 Q3	$27K	Hold	77	–	–	﹤0.01%	729
2023 Q2	$27K	Hold	77	–	–	﹤0.01%	683
2023 Q1	$24K	Hold	77	–	–	﹤0.01%	706
2022 Q4	$22K	Sell	77 -19	-20%	-$5.79K	﹤0.01%	745
2022 Q3	$28K	Buy	96 +19	+25%	+$5.47K	﹤0.01%	669
2022 Q2	$22K	Hold	77	–	–	﹤0.01%	699
2022 Q1	$20K	Hold	77	–	–	﹤0.01%	675
2021 Q4	$17K	Hold	77	–	–	﹤0.01%	747
2021 Q3	$14K	Hold	77	–	–	﹤0.01%	754
2021 Q2	$16K	Hold	77	–	–	﹤0.01%	693
2021 Q1	$17K	Hold	77	–	–	﹤0.01%	734
2020 Q4	$18K	Hold	77	–	–	﹤0.01%	528
2020 Q3	$21K	Hold	77	–	–	﹤0.01%	500
2020 Q2	$22K	Hold	77	–	–	﹤0.01%	465
2020 Q1	$18K	Hold	77	–	–	﹤0.01%	463
2019 Q4	$17K	Hold	77	–	–	﹤0.01%	506
2019 Q3	$13K	Sell	77 -15	-16%	-$2.65K	﹤0.01%	520
2019 Q2	$17K	Buy	92 +15	+19%	+$2.62K	﹤0.01%	477
2019 Q1	$14K	Buy	+77	New	+$14.2K	﹤0.01%	482

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Analysts LLC's VRTX Position: Q1 2026 in Review

Capital Analysts LLC increased its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q1 2026, buying an estimated $1.4K and bringing the position to 119 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #928.

Capital Analysts LLC first reported a position in VRTX in Q1 2019 and has held it in 29 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Capital Analysts LLC held 119 shares of Vertex Pharmaceuticals worth $53K as of Q1 2026.
Capital Analysts LLC bought 3 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.4K.
Vertex Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #928 holding.
Capital Analysts LLC first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.